If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Single-chain relaxin analog · RXFP1 agonist
Research documentation
Ask sales for the B7-33 batch COA and the analytical evidence needed to qualify the material for your study. Confirm the available purity and identity records, lot continuity, handling information, and method requirements before ordering.
Overview
B7-33 is a 27-residue single-chain analog of native relaxin-2 (H2-relaxin) that keeps the RXFP1-agonist activity of the parent hormone while dispensing with its disulfide-linked two-chain architecture. It behaves as a biased RXFP1 agonist, favoring signaling through the ERK1/2 arm downstream of the receptor while engaging the cAMP arm only weakly; the developers reasoned this bias could deliver relaxin's anti-fibrotic and tissue-remodeling actions without the dose-limiting cardiovascular effects tied to balanced full agonism. Lyochem supplies B7-33 as a lyophilized 27-residue reference standard to a ≥99.0% HPLC purity specification. Because it is a linear single chain carrying no disulfide bridges, it is far more tractable to synthesize than the disulfide-bonded native relaxin heterodimer, a practical dividend of the biased-agonist design that sits alongside its pharmacology. Every released lot comes with its batch COA reporting RP-HPLC purity and mass-spectrometric identity, with sequence verification supplied on request. Fill sizes of 2 mg and 10 mg serve typical fibrosis, cardiovascular, and tissue-remodeling research models.
Applications & buyer fit
Repair peptides — BPC-157, TB-500, B7-33, PEG-MGF — ship primarily to research laboratories. The applicable batch COA records the tests actually completed. Tandem-MS sequence evidence is an additional agreed scope when the buyer's written procedure requires it, not a blanket requirement to repeat release testing.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Every lot has its own batch-specific CoA — HPLC purity and MS identity, plus any analytical scope agreed at quote stage — tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, not for in-vitro diagnostic use. For in vivo workflows, request bacterial-endotoxin and microbial-limit testing on the specific lot at quote stage.
Frequently asked questions
Start with the COA matched to the offered batch. If the buyer's written procedure needs added RP-HPLC, ESI-MS, or LC-MS/MS evidence, confirm availability and define the method, acceptance rule, sample, reporting, timing, and cost before quotation. The linear sequence has no disulfide-regiochemistry question, but no fixed analytical panel is implied for every lot.
Review the matching batch COA to see which content, counter-ion, or water results were actually recorded. If the buyer's calculation requires additional measurements, agree that scope with sales before quotation rather than assuming those items are standard on every COA.
Related peptides